BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

Clinical trial NCT07618624 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07618624
Sponsor: Sun Yat-sen University
Status: ENROLLING_BY_INVITATION
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Head and Neck Squamous Cell Carcinoma Head and Neck Cancer

Start date: 2026-04-20
Primary completion: 2027-12-31
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.